456 search results for “medieval een lacdr” in the Student website
-
Andrea Reyes ElizondoFaculty of Social and Behavioural Sciences
-
Emma GrootveldFaculty of Humanities
-
Nadine AkkermanFaculty of Humanities
-
Wouter WagemakersFaculty of Humanities
-
Iris van Wissen -
Anna Witteveen -
Marije Niemeijer -
Natalia Ortiz Zacarias -
Eveline de Vlieger -
Mariona Oliver Lloberas -
Roy Snijckers -
Danxia Zhao -
Maria Xiberras -
Pier Lindenbergh -
Romy Dijkland -
Jeroen Molenaar -
Frank Schaftenaar -
Chenlin Feng -
Aole Zheng -
Tessa Hagens -
Sophieke Lems -
Marloes van Oosterhout -
Gabriela Schäfer -
Yuliya Shakalisava -
Marjo de Graauw -
Piet Hein Graaf -
Jos Jonkers
-
Gerard van Westen -
Gideon Kersten -
Barend Mons -
Sylvia Le Dévédec -
Marie Depuydt -
Bonan Zhao -
Anne Charlotte Dubbelman -
Better treatment of skin diseases thanks to NWA grant of 11.7 million euros
Patients with skin diseases such as eczema and psoriasis, sometimes spend a lifetime searching for the right medication. To help these patients faster and better, scientists across the country are joining forces. The Next Generation ImmunoDermatology (NGID) project, with LACDR professor Robert Rissmann…
-
Leiden scientists join national effort to advance nanomedicine
A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.
-
Gilles van Wezel steps down as SD of the IBL: Hubertus Irth appointed as temporary replacement
Gilles van Wezel will step down as Scientific Director (SD) of the Institute of Biology Leiden (IBL) as of June 17th. He has held this position since September 2018. Van Wezel will be temporarily succeeded by Hubertus Irth, the current SD of the Leiden Academic Centre for Drug Research (LACDR). Irth…
-
During the next pandemic, this mathematical model will speed up the search for treatment
Do you recall all those drugs that were hastily proposed as potential treatments for COVID-19? In the event of a future pandemic, the goal is to offer an effective treatment more quickly and efficiently. To achieve this, a team led by Coen van Hasselt is developing a platform that can speed up the process…
-
Unlocking the secrets of DNA repair: Sarah’s curiosity might lead to new cancer treatments
How do cells repair their damaged DNA—and what happens when that process is hindered and cancer arises? Sarah Moser has taken a closer look during her PhD, uncovering surprising insights that could help improve future cancer treatments.
-
Constant HijzenFaculteit Governance and Global Affairs
-
Daan WeggemansFaculteit Governance and Global Affairs
-
Sylvestre Bonnet -
Edwin BakkerFaculteit Governance and Global Affairs
-
Fred JanssenICLON
-
Thijs Brocades ZaalbergFaculty of Humanities
-
Minors in AI, Data & Digitialisation in Delft, Leiden and Rotterdam
The universities of Delft, Leiden and Rotterdam are working together to show their students what artificial intelligence (AI) means for their own field. Three AI minors will start in the 2022 – 2023 academic year and will answer questions such as: ‘How best can you use AI in your research discipline?’…
-
Remarkable PhD research: diagnosing sepsis in premature babies
How can we diagnose the life-threatening condition sepsis in premature babies as quickly and accurately as possible? That is what PhD student Manchu Thangavelu from the Leiden Academic Centre for Drug Research (LACDR) wants to figure out.
-
Time Talks: Temporality Across Disciplines
Lecture, YAL & Studium Generale
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
A future with tailored therapy for patients with atherosclerosis
The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.